| Literature DB >> 27847310 |
Doriane Lorendeau1, Gianmarco Rinaldi1, Ruben Boon2, Pieter Spincemaille3, Kristine Metzger1, Christian Jäger4, Stefan Christen1, Xiangyi Dong4, Sabine Kuenen5, Karin Voordeckers6, Patrik Verstreken5, David Cassiman7, Pieter Vermeersch8, Catherine Verfaillie2, Karsten Hiller4, Sarah-Maria Fendt9.
Abstract
Mutations in succinate dehydrogenase (SDH) are associated with tumor development and neurodegenerative diseases. Only in tumors, loss of SDH activity is accompanied with the loss of complex I activity. Yet, it remains unknown whether the metabolic phenotype of SDH mutant tumors is driven by loss of complex I function, and whether this contributes to the peculiarity of tumor development versus neurodegeneration. We addressed this question by decoupling loss of SDH and complex I activity in cancer cells and neurons. We found that sole loss of SDH activity was not sufficient to recapitulate the metabolic phenotype of SDH mutant tumors, because it failed to decrease mitochondrial respiration and to activate reductive glutamine metabolism. These metabolic phenotypes were only induced upon the additional loss of complex I activity. Thus, we show that complex I function defines the metabolic differences between SDH mutation associated tumors and neurodegenerative diseases, which could open novel therapeutic options against both diseases.Entities:
Keywords: (13)C metabolic flux analysis; 3-nitropropionic acid (PubChem CID: 1678); Ataxia; Atpenin A5 (PubChem CID: 54676868); CB-839 (PubChem CID: 71577426); Complex I of the electron transport chain; Gastrointestinal stromal tumors; Leigh syndrome; Leukodystrophy; Mitochondrial respiration; Paraganglioma; Pyruvate carboxylase; Reductive glutamine metabolism; SDH mutations; Succinate dehydrogenase; rotenone (PubChem CID: 6758)
Mesh:
Substances:
Year: 2016 PMID: 27847310 DOI: 10.1016/j.ymben.2016.11.005
Source DB: PubMed Journal: Metab Eng ISSN: 1096-7176 Impact factor: 9.783